GetEsoteric Admin

GetEsoteric Admin’s Docs ▸ Edited By Me

You are viewing all docs.

Filter by: Attachments Search Tag

Has attachment	Title	Author	Created	Last Edited	Tags
	This is a test document! What do you think of this post?Awesome (0)Interesting (0)Useful (0)Boring (0)Sucks (0) Twitter Facebook Reddit Blogger Pinterest Gmail What do you think of this post? Awesome (0) Interesting (0) Useful (0) Boring (0) Sucks (0) Open Forums, General Discussions.’s Docs ▸ Test Docs Read \| History Attachments Desert-Boat1Shirt.png	GetEsoteric Admin	June 21, 2018	June 21, 2018
	Pfizer latest docs as of May 2nd! Pfizer latest docs as of May 2nd! What do you think of this post?Awesome (0)Interesting (0)Useful (0)Boring (0)Sucks (0) Twitter Facebook Reddit Blogger Pinterest Gmail What do you think of this post? Awesome (0) Interesting (0) Useful (0) Boring (0) Sucks (0) Read \| History Attachments CRFs-for-site-1081.pdf Supplemental-Index-12-22-21.pdf STN-125742_0_0-Section-2.7.4-summary-clin-safety.pdf STN-125742_0_0-Section-2.7.3-Summary-of-Clinical-Efficacy.pdf signed-F21-5683-CBER-Dec-13-2021-Response-Letter.pdf STN-125742_0_0-Section-2.5-Clinical-Overview.pdf CRFs-for-site-1055.pdf BATES-FDA-CBER-2021-5683-0002374_adc19ef-ve-sev-cov-7pd2-wo-eval-sas.txt BATES-FDA-CBER-2021-5683-0002375_addv-sas.txt BATES-FDA-CBER-2021-5683-0002373_adc19ef-ve-sev-cov-7pd2-eval-sas.txt BATES-FDA-CBER-2021-5683-0002372_adc19ef-ve-cov-7pd2-eval-sas.txt Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-B.pdf Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-A.pdf BATES-92_adc19ef-ve-cov-7pd2-wo-eval-sas.txt 5.3.6-postmarketing-experience.pdf 5.2-listing-of-clinical-sites-and-cvs-pages-1-41.pdf 5.2-tabular-listing.pdf 125742_S1_M5_5351_c4591001-interim-mth6-invest-signature.pdf reissue_5.3.6-postmarketing-experience.pdf 125742_S1_M5_5351_c4591001-interim-mth6-demographics.pdf 125742_S1_M5_5351_c4591001-interim-mth6-adverse-events-sensitive.pdf 125742_S1_M5_5351_c4591001-interim-mth6-audit-certificates.pdf 125742_S1_M5_5351_c4591001-fa-interim-sponsor-signature.pdf 125742_S1_M5_5351_c4591001-fa-interim-randomization-sensitive.pdf 125742_S1_M5_5351_c4591001-fa-interim-sample-crf.pdf 125742_S1_M5_5351_c4591001-fa-interim-randomization.pdf 125742_S1_M5_5351_c4591001-fa-interim-publications.pdf 125742_S1_M5_5351_c4591001-fa-interim-invest-signature.pdf 125742_S1_M5_5351_c4591001-fa-interim-protocol-deviations.pdf 125742_S1_M5_5351_c4591001-fa-interim-iec-irb-consent-form.pdf 125742_S1_M5_5351_c4591001-fa-interim-demographics.pdf 125742_S1_M5_5351_c4591001-fa-interim-audit-certificates.pdf 125742_S1_M1_priority-review-request-1.pdf FDA-CBER-2021-5683-0023983-to-0023984_125742_S1_M5_c4591001-A-report-cci-rheumatic.xlsx FDA-CBER-2021-5683-0023987_125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.xlsx FDA-CBER-2021-5683-0023979-to-0023980_125742_S1_M5_c4591001-A-report-cci-renal.xlsx FDA-CBER-2021-5683-0023971-to-0023972_125742_S1_M5_c4591001-A-report-cci-periph-vasc.xlsx FDA-CBER-2021-5683-0023975-to-0023976_125742_S1_M5_c4591001-A-report-cci-pulmonary.xlsx FDA-CBER-2021-5683-0023965_125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.xlsx FDA-CBER-2021-5683-0023967_125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.xlsx FDA-CBER-2021-5683-0023960_125742_S1_M5_c4591001-A-report-cci-mi.xlsx FDA-CBER-2021-5683-0023963_125742_S1_M5_c4591001-A-report-cci-mild-liver.xlsx FDA-CBER-2021-5683-0023955-to-0023958_125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.xlsx FDA-CBER-2021-5683-0023936-to-0023937_125742_S1_M5_c4591001-A-report-cci-leukemia.xlsx FDA-CBER-2021-5683-0023944-to-0023950_125742_S1_M5_c4591001-A-report-cci-lymphoma.xlsx FDA-CBER-2021-5683-0023930_125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.xlsx FDA-CBER-2021-5683-0023932_125742_S1_M5_c4591001-A-report-cci-hemiplegia.xlsx FDA-CBER-2021-5683-0023928_125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.xlsx FDA-CBER-2021-5683-0023924_125742_S1_M5_c4591001-A-report-cci-chf.xlsx FDA-CBER-2021-5683-0023926_125742_S1_M5_c4591001-A-report-cci-dementia.xlsx FDA-CBER-2021-5683-0023895-to-0023915_125742_S1_M5_c4591001-A-report-cci-any-malignancy.xlsx FDA-CBER-2021-5683-0023919-to-0023921_125742_S1_M5_c4591001-A-report-cci-cerebrovascular.xlsx FDA-CBER-2021-5683-0023711-to-0023875_125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.xlsx FDA-CBER-2021-5683-0023878_125742_S1_M5_c4591001-A-report-cci-aids-hiv.xlsx FDA-CBER-2021-5683-0023550-to-0023569_125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.xlsx FDA-CBER-2021-5683-0023523-to-0023538_125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.xlsx FDA-CBER-2021-5683-0023540_125742_S1_M5_c4591001-A-comorbidity-categories.xlsx FDA-CBER-2021-5683-0023490-to-0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsx FDA-CBER-2021-5683-0023500-to-0023507_125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.xlsx FDA-CBER-2021-5683-0023032-to-0023065_125742_S1_M5_c4591001-A-P-adva-sas.txt FDA-CBER-2021-5683-0022867-to-0023006_125742_S1_M5_c4591001-A-P-adsl-sas.txt FDA-CBER-2021-5683-0023007-to-0023031_125742_S1_M5_c4591001-A-P-adsympt-sas.txt FDA-CBER-2021-5683-0022766-to-0022792_125742_S1_M5_c4591001-A-P-adsl-fu-d2-p3-saf-sas.txt FDA-CBER-2021-5683-0022793-to-0022866_125742_S1_M5_c4591001-A-P-adsl-s005-demo-all-p3-saf-sas.txt FDA-CBER-2021-5683-0022692-to-0022765_125742_S1_M5_c4591001-A-P-adsl-demo-7d-wwo-eval-eff-sas.txt FDA-CBER-2021-5683-0022601-to-0022617_125742_S1_M5_c4591001-A-P-admh-sas.txt FDA-CBER-2021-5683-0022618-to-0022691_125742_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-sas.txt FDA-CBER-2021-5683-0022561-to-0022567_125742_S1_M5_c4591001-A-P-adds-sas.txt FDA-CBER-2021-5683-0022568-to-0022600_125742_S1_M5_c4591001-A-P-adfacevd-sas.txt FDA-CBER-2021-5683-0022346-to-0022364_125742_S1_M5_c4591001-A-P-adcm-sas.txt FDA-CBER-2021-5683-0022365-to-0022560_125742_S1_M5_c4591001-A-P-adds-s002-all-p3-rand-sas.txt FDA-CBER-2021-5683-0022326-to-0022345_125742_S1_M5_c4591001-A-P-adcevd-sas.txt FDA-CBER-2021-5683-0022063-to-0022135_125742_S1_M5_c4591001-A-P-adce-s010-lr-p3-saf-sas.txt FDA-CBER-2021-5683-0022136-to-0022325_125742_S1_M5_c4591001-A-P-adce-s020-se-p3-saf-sas.txt FDA-CBER-2021-5683-0022041-to-0022053_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-sas.txt FDA-CBER-2021-5683-0022054-to-0022062_125742_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-pd1-aai-sas.txt FDA-CBER-2021-5683-0021981-to-0022027_125742_S1_M5_c4591001-A-P-adc19ef-sas.txt FDA-CBER-2021-5683-0022028-to-0022040_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-sg-eval-sas.txt FDA-CBER-2021-5683-0021964-to-0021980_125742_S1_M5_c4591001-A-P-adae-vax-tier2-p3-saf-sas.txt FDA-CBER-2021-5683-0021930-to-0021943_125742_S1_M5_c4591001-A-P-adae-s092-cr-cut-p3x-saf-sas.txt FDA-CBER-2021-5683-0021944-to-0021963_125742_S1_M5_c4591001-A-P-adae-sas.txt FDA-CBER-2021-5683-0021902-to-0021915_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf2-sas.txt FDA-CBER-2021-5683-0021916-to-0021929_125742_S1_M5_c4591001-A-P-adae-s092-all-unb-p3-saf-sas.txt FDA-CBER-2021-5683-0021888-to-0021901_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf1-sas.txt 125742_S1_M5_CRF_c4591001-1085-10851216.pdf 125742_S1_M5_CRF_c4591001-1085-10851246.pdf 125742_S1_M5_CRF_c4591001-1085-10851129.pdf 125742_S1_M5_CRF_c4591001-1085-10851018.pdf 125742_S1_M5_CRF_c4591001-1085-10851116.pdf 125742_S1_M5_c4591001-T-S-updated-reacto-tlf.pdf 125742_S1_M5_c4591001-T-S-suppl-arg.pdf 125742_S1_M5_c4591001-T-S-roadmap.pdf 125742_S1_M5_c4591001-T-S-summary-differences-csr-vs-update.pdf 125742_S1_M5_c4591001-T-S-final-reacto-tables-track.pdf 125742_S1_M5_c4591001-A-report-cci-renal.pdf 125742_S1_M5_c4591001-A-report-cci-rheumatic.pdf 125742_S1_M5_c4591001-A-report-cci-periph-vasc.pdf 125742_S1_M5_c4591001-A-report-cci-pulmonary.pdf 125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.pdf 125742_S1_M5_c4591001-A-report-cci-mild-liver.pdf 125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.pdf 125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.pdf 125742_S1_M5_c4591001-A-report-cci-mi.pdf 125742_S1_M5_c4591001-A-report-cci-lymphoma.pdf 125742_S1_M5_c4591001-A-report-cci-hemiplegia.pdf 125742_S1_M5_c4591001-A-report-cci-leukemia.pdf 125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.pdf 125742_S1_M5_c4591001-A-report-cci-dementia.pdf 125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.pdf 125742_S1_M5_c4591001-A-report-cci-cerebrovascular.pdf 125742_S1_M5_c4591001-A-report-cci-chf.pdf 125742_S1_M5_c4591001-A-report-cci-any-malignancy.pdf 125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.pdf 125742_S1_M5_c4591001-A-report-cci-aids-hiv.pdf 125742_S1_M5_c4591001-A-comorbidity-categories.pdf 125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.pdf 125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.pdf 125742_S1_M5_c4591001-A-bmi-12-15-scale.pdf 125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.pdf 125742_S1_M5_c4591001-A-adrg.pdf 125742_S1_M5_5351_c4591001-interim-mth6-protocol.pdf 125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.pdf 125742_S1_M5_5351_c4591001-interim-mth6-oversight-committees.pdf 125742_S1_M5_5351_c4591001-fa-interim-protocol.pdf 125742_S1_M5_5351_c4591001-fa-interim-oversight-committees.pdf 125742_S1_M5_5351_c4591001-fa-interim-lab-measurements.pdf 125742_S1_M5_5351_c4591001-fa-interim-lab-measurements-sensitive.pdf 125742_S1_M5_5351_c4591001-fa-interim-excluded-patients-sensitive.pdf 125742_S1_M5_5351_c4591001-fa-interim-errata.pdf 125742_S1_M5_5351_c4591001-fa-interim-excluded-patients.pdf 125742_S1_M5_5351_c4591001-fa-interim-efficacy-response.pdf 125742_S1_M5_5351_c4591001-fa-interim-compliance.pdf 125742_S1_M5_5351_c4591001-fa-interim-compliance-sensitive.pdf 125742_S1_M5_5351_c4591001-ad-hoc-label-tables.pdf 125742_S1_M4_4223_R-20-0072.pdf 125742_S1_M2_27_synopses-indiv-studies.pdf 125742_S1_M4_4223_185350.pdf 125742_S1_M2_26_pharmkin-written-summary.pdf 125742_S1_M2_27_literature-references.pdf 125742_S1_M2_26_pharmkin-tabulated-summary.pdf 125742_S1_M2_22_introduction.pdf 125742_S1_M2_24_nonclinical-overview.pdf 125742_S1_M1_waiver-req-designated-suffix.pdf 125742_S1_M1_us-agent-authorization.pdf 125742_S1_M1_userfee.pdf 125742_S1_M1_trans-of-oblig.pdf 125742_S1_M1_ipsp-agreed-letter.pdf 125742_S1_M1_priority-review-request.pdf 125742_S1_M1_financial-cert-bias.pdf 125742_S1_M1_fast-track-designation.pdf 125742_S1_M1_financial-cert-3454.pdf 125742_S1_M1_exclusivity-claim.pdf 125742_S1_M1_cover.pdf 125742_S1_M1_debarment.pdf 125742_S1_M1_3674.pdf 125742_S1_M1_356h.pdf CRFs-for-site-1128.pdf CRFs-for-site-1096.pdf	GetEsoteric Admin	May 7, 2022	May 7, 2022
	There are no docs for this view.

Viewing 1-2 of 2 docs

Translate »